This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NW Bio's International Phase III GBM Brain Trial Is Subject Of BBC TV Report In The UK

BETHESDA, Md., Dec. 30, 2013 /PRNewswire/ --  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that the British Broadcasting Company (BBC) TV network has broadcast a report profiling the first European patient in the Company's Phase III clinical trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM), the most common and aggressive form of brain cancer.  This patient was operated on in June, 2013, by Dr. Keyoumars Ashkan, a senior neurosurgeon at Kings College Hospital and the lead investigator for the trial in the U.K., to remove his brain tumor and enable him to enter the DCVax-L trial.


The BBC report can be seen at The BBC report notes that immune therapies are emerging as one of the most important areas in cancer research, and that the Phase III trial of DCVax-L for GBM is one of the most advanced involving personalized immune therapies.  The profiled patient is well known British Shakespearean actor Robert Demeger, who has appeared regularly on the stage and in the popular TV series Doctor Who.  A further interview of Mr. Demeger can also be found on the BBC website (see "Related Videos" at the same link), in which Mr. Demeger describes in more detail his own condition and circumstances.

As noted by Dr. Ashkan in the BBC report, there is substantial variation among patients with the "same" GBM brain cancer.  One-size-fits-all treatments cannot address this patient-to-patient variation.  Personalized treatments are needed in order to address the variability. As described in the BBC report, DCVax-L is a personalized treatment made from the patient's own immune cells (dendritic cells) and biomarkers from the patient's own tumor. 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,776.43 +304.06 1.85%
S&P 500 1,987.05 +35.69 1.83%
NASDAQ 4,781.2640 +73.4890 1.56%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs